MedTrace Logo

Subject Preference for Scalp Psoriasis Treatment

NCT00438399 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2021-02-18

Study results available
· View outcomes & findings →

Summary

The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress.

Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair.

The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects.

The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.

Conditions

  • Scalp Psoriasis

Interventions

DRUG

C. propionate - Corticosteroid 1

Twice daily application

DRUG

C. propionate- Corticosteroid 2

Twice daily application

DRUG

C. propionate -Corticosteroid 3

Twice daily application

DRUG

Corticosteroid 1- C. propionate

Twice daily application

DRUG

Corticosteroid 2 - C. propionate

Twice daily application

DRUG

Corticosteroid 3 - C. propionate

Twice daily application

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Alberto Giannetti, Professor · Clinica Dermatologica Azienda Ospedaliera Policinico di Modena - Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-01-31
Completion
2008-02-29

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00438399 on ClinicalTrials.gov